AI/Machine Learning Pre-Conference Focus Day
Tuesday, March 19, 2024

8:00 am Registration & Morning Coffee

8:55 am Chair’s Opening Remarks

Leveraging AI to Classify IBD Subtypes for Improved Disease Management

9:00 am Wearable and Connected Technologies: Harnessing AI & Machine Learning in the Management of IBD

  • Robert Hirten Clinical Director, The Hasso Plattner Institute of Digital Heath at Mount Sinai; Associate Professor of Medicine & Artificial..., Icahn School of Medicine at Mount Sinai


  • Discuss how non-invasive wearable devices and the physiological data they collect can be used in the management of health and disease
  • Discuss how we can leverage the data collected from novel technologies through AI/ML to monitor IBD activity
  • Discuss how wearable and connected technologies can non-invasively monitor for drug response

9:30 am Panel Discussion: Using AI-Enhanced Phenotyping to Provide Novel Understanding of IBD Heterogeneity

  • Marc Sze Principal Scientist, Merck & Co
  • Edward O’Brien Senior Scientist - Microbiome Sciences, Seres Therapeutics
  • Frederic Baribaud Senior Lead - Translational Early Program, Bristol Myers Squibb
  • Frank Li Director, Computational Biology, Boehringer Ingelheim


  • To what extent will AI reshape the classification of IBD subtypes?
  • What insights does classify IBD subtypes provide into disease heterogeneity?
  • Delving into AI-enhanced phenotyping for tailoring bespoke treatment options 

10:30 am Morning Networking Break

Optimizing Data Handling to Improve Patient Selection for Better Personalized IBD Treatment Options

11:30 am Practical Considerations of Application in IBD to Improve Patient Care


  • Real-world applications of AI in personalized medicine for IBD, including how AI-driven tools could be used to diagnose and monitor patient progress
  • How can we integrate AI effectively and ethically into clinical practice to ensure regulatory considerations, data privacy, and strategies during a successful implementation?

12:00 pm AI for multi-omics analysis and discovery of biomarkers of disease progression in Crohn’s Disease

  • Andres Hurtado-Lorenzo Senior Vice President, Translational Research & IBD Ventures, Crohn’s & Colitis Foundation


  • Discuss the implementation of machine learning for identification of prognostic biomarkers of progression to complicated disease behaviour using transcriptomics and proteomics data sets.
  • Discuss whether AI-based immunoprofiling could support the identification of disease specific autoantibodies for patient subtyping.

12:30 pm Lunch & Networking Break

Harnessing AI/ML to Predict Patient Progression for Improved Clinical Outcomes for IBD Patients

1:30 pm Roundtable Discussion: Enhancing Clinical Trial Design to Effectively Catalyse Clinical Studies & Accelerate IBD Drug Development

  • Mera Telley Vice President, Genetics & Precision Immunology, Alumis


  • How can utilise AI to improve patient selection and eligibility screening for novel therapeutics?
  • How can we use the wealth of clinical data for protocol optimization within the context of clinical design?
  • Can we use AI/ML for predictive analytics, identifying potential complications or negative reactions in early stages of clinical trials?
  • Could we implement real-time patient monitoring to identify trends or anomalies that may require immediate attention?
  • Are modalities required for companion diagnostics sufficient to implement into clinical trials?

2:30 pm Using AI/ML to Combine Prognosis & Stratification to Predict Patient Progression


  • Exploring the potential for AI-driven predictive models in stratifying IBD by forecasting disease progression
  • What are the possibilities for drug developers and healthcare providers to leverage these models for proactive and personalized care?
  • Can we utilise AI/ML to better understand the placebo response

3:00 pm Navigating AI in Clinical Trials: Unraveling Challenges in Histology-based Disease Assessment for IBD Patients


  • Annotation Granularity: Can we rely on the AI model trained without detailed annotations of tissue pathologies?
  • Batch Effects on AI Models: Do batch effects negatively affect the AI reasoning process and how to prevent them?
  • Matching Expert Accuracy: Do clinical conclusions about the disease state derived from the AI model, matching histology experts' accuracy, align with clinicians' assessments?

3:00 pm Afternoon Networking Break

Wielding Machine Learning to Optimize Drug Response Rate & Efficacy for Enhanced Therapeutic Potential

4:00 pm Harnessing the Power of AI/ML for Patient Selection


  • Identifying biomarkers for insights to subpopulations suitable for therapeutic mechanisms to work
  • Identifying subpopulations to optimize the drug response rate

4:30 pm AI-Driven Drug Repurposing: Cross Learning Opportunities into Expanding the Therapeutic Arsenal to Optimise Drug Efficacy

  • Mera Telley Vice President, Genetics & Precision Immunology, Alumis


  • Is it possible to leverage AI/ML to repurpose existing drugs to better target auto-immune diseases?
  • How can we implement cross-learning opportunities, exploring distinct diseases, to optimize drug discovery?
  • Utilising the power of AI/ML to faster discover effective and novel drugs to target already-established therapeutic targets

5:00 pm Chair’s Closing Remarks & End of Pre-Conference Focus Day